» Articles » PMID: 22672386

Expression of Proto-oncogene KIT is Up-regulated in Subset of Human Meningiomas

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2012 Jun 8
PMID 22672386
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: KIT is a proto-oncogene involved in diverse neoplastic processes. Aberrant kinase activity of the KIT receptor has been targeted by tyrosine kinase inhibitor (TKI) therapy in different neoplasias. In all the earlier studies, KIT expression was reported to be absent in meningiomas. However, we observed KIT mRNA expression in some meningioma cases. This prompted us to undertake its detailed analyses in meningioma tissues resected during 2008-2009.

Methods: Tumor tissues and matched peripheral blood samples collected from meningioma patients were used for detailed molecular analyses. KIT expression was ascertained immunohistochemically and validated by immunoblotting. KIT and KITLG transcript levels were discerned by reverse transcription quantitative real-time PCR (RT-qPCR). Similarly, KIT amplification and allele loss were assessed by quantitative real-time (qPCR) and validated by fluorescence in situ hybridization (FISH) on the neoplastic tissues. Possible alterations of the gene at the nucleotide level were analyzed by sequencing.

Results: Contrary to earlier reports, KIT expression, was detected immunohistochemically in 20.6% meningioma cases (n = 34). Receptor (KIT) and ligand (KITLG) transcripts monitored by RT-qPCR were found to co-express (p = 0.048) in most of the KIT immunopositive tumors. 1/7 KIT positive meningiomas showed allele loss corroborated by reduced FISH signal in the corresponding neoplastic tissue. Sequence analysis of KIT showed M541L substitution in exon 10, in one of the immunopositive cases. However, its biological consequence remains to be uncovered.

Conclusions: This study clearly demonstrates KIT over-expression in the human meningiomas. The data suggest that up-regulated KIT transcription (p < 0.001), instead of gene amplification (p > 0.05), is a likely mechanism responsible for altered KIT expression. Thus, KIT is a potential candidate for detailed investigation in the context of meningioma pathogenesis.

Citing Articles

Domestic Animal Models of Central Nervous System Tumors: Focus on Meningiomas.

Tomanelli M, Florio T, Vargas G, Pagano A, Modesto P Life (Basel). 2023; 13(12).

PMID: 38137885 PMC: 10744527. DOI: 10.3390/life13122284.


Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma.

Roesler R, Souza B, Isolan G Int J Mol Sci. 2021; 22(21).

PMID: 34768783 PMC: 8583503. DOI: 10.3390/ijms222111352.


Next generation sequencing identifies novel potential actionable mutations for grade I meningioma treatment.

Pepe F, Pisapia P, De Caro M, Conticelli F, Malapelle U, Troncone G Histol Histopathol. 2019; 35(7):741-749.

PMID: 31872418 DOI: 10.14670/HH-18-195.


SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma.

Saini M, Verma A, Mathew S Cell Death Dis. 2018; 9(2):237.

PMID: 29445192 PMC: 5833614. DOI: 10.1038/s41419-018-0261-2.


Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma.

Li Z, Stolzel F, Onel K, Sukhanova M, Mirza M, Yap K Leukemia. 2015; 29(10):2113-6.

PMID: 25787914 PMC: 4575593. DOI: 10.1038/leu.2015.81.

References
1.
Perrone F, Tamborini E, Dagrada G, Colombo F, Bonadiman L, Albertini V . 9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations. Cancer. 2005; 104(1):159-69. DOI: 10.1002/cncr.21113. View

2.
Broudy V . Stem cell factor and hematopoiesis. Blood. 1997; 90(4):1345-64. View

3.
Sihto H, Tynninen O, Butzow R, Saarialho-Kere U, Joensuu H . Endothelial cell KIT expression in human tumours. J Pathol. 2007; 211(4):481-8. DOI: 10.1002/path.2125. View

4.
Mathew S, Murty V, Hunziker W, Chaganti R . Subregional mapping of 13 single-copy genes on the long arm of chromosome 12 by fluorescence in situ hybridization. Genomics. 1992; 14(3):775-9. DOI: 10.1016/s0888-7543(05)80184-3. View

5.
Stanulla M, Welte K, Hadam M, Pietsch T . Coexpression of stem cell factor and its receptor c-Kit in human malignant glioma cell lines. Acta Neuropathol. 1995; 89(2):158-65. DOI: 10.1007/BF00296360. View